Inhibitory Effects of Epigallocatechin-3-Gallate on Microsomal Cyclooxygenase-1 Activity in Platelets

Dong-Ha Lee¹, Yun-Jung Kim¹, Hyun-Hong Kim¹, Hyun-Jeong Cho², Jin-Hyeob Ryu¹, Man Hee Rhee³ and Hwa-Jin Park¹,*

¹Department of Biomedical Laboratory Science, College of Biomedical Science and Engineering and Regional Research Center, Inje University, Gimhae 621-749, ²Department of Biomedical Laboratory Science, College of Medical Science, Konyang University, Daejeon 302-718, ³Laboratory of Veterinary Physiology & Signaling, College of Veterinary Medicine, Kyungpook National University, Daegu 702-701, Republic of Korea

Abstract
In this study, we investigated the effect of (−)-epigallocatechin-3-gallate (EGCG), a major component of green tea catechins from green tea leaves, on activities of cyclooxygenase (COX)-1 and thromboxane synthase (TXAS), thromboxane A₂ (TXA₂) production associated microsomal enzymes. EGCG inhibited COX-1 activity to 96.9%, and TXAS activity to 20% in platelet microsomal fraction having cytochrome c reductase (an endoplasmic reticulum marker enzyme) activity and expressing COX-1 (70 kDa) and TXAS (58 kDa) proteins. The inhibitory ratio of COX-1 to TXAS by EGCG was 4.8. These results mean that EGCG has a stronger selectivity in COX-1 inhibition than TXAS inhibition. In special, a nonsteroid anti-inflammatory drug aspirin, a COX-1 inhibitor, inhibited COX-1 activity by 11.3% at the same concentration (50 μM) as EGCG that inhibited COX-1 activity to 96.9% as compared with that of control. This suggests that EGCG has a stronger effect than that of aspirin on inhibition of COX-1 activity. Accordingly, we demonstrate that EGCG might be used as a crucial tool for a strong negative regulator of COX-1/TXA₂ signaling pathway to inhibit thrombotic disease-associated platelet aggregation.

Key Words: (−)-Epigallocatechin-3-gallate (EGCG), Aspirin, Microsomal fraction, Cyclooxygenase-1, Thromboxane synthase

INTRODUCTION
An important role in the mechanism that agonists induce platelet aggregation is played by an aggregation-inducing molecule thromboxane A₂ (TXA₂) formation (Malmsten et al., 1975; Lewis and Watts, 1982; Li et al., 2010), which can cause circulatory disorders such as thrombosis, atherosclerosis, and myocardial infarction (Schwartz et al., 1990). TXA₂ is generated from arachidonic acid (AA) released when membrane phospholipids are broken down by diverse agonists such as collagen, thrombin, and ADP, and powerfully induces platelet activation and vasoconstriction as an autacodial action (Hamberg et al., 1975; Samuelsson et al., 1978; Gresele et al., 1991). TXA₂ production associated enzymes are cyclooxygenase (COX)-1 and thromboxane synthase (TXAS), which are located at microsomes (Carey et al., 1982). COX-1 produces prostaglandin (PG)G₂ from substrate AA, TXAS produces TXA₂ from PGH₁ that oxidized from PGG₂ by endoperoxidase. Therefore, inhibition of COX-1 or TXAS is very useful to evaluate an antiplatelet effect of any substance or compound. For instance, COX-1 inhibitor aspirin and TXAS inhibitor ozagrel are being used as anti-platelet agents (Patrono, 2001).

A major catechin analogue (−)-epigallocatechin-3-gallate (EGCG, Fig. 2A) from green tea has a galloyl group at the 3’ position of catechin, and is known to have an anti-platelet activity by inhibiting p38 mitogen-activated protein kinase, and extracellular signal-regulated kinase-1/2 (Lili et al., 2003) and by reducing thrombin-induced [Ca²⁺] increase via inhibition of Syk and Lyn activities (Deana et al., 2003). EGCG has also been reported to inhibit collagen-induced phospholipase C-γ₂ activity and TXA₂ production (Jin et al., 2008). With regard to the regulatory effects of EGCG on COX-1 or TXAS activity, it is reported that EGCG failed to inhibit COX-1 and TXAS activity (Jin et al., 2008). In addition, it is known that EGCG did not affect COX-1 expression in human prostate carcinoma cells (Hussain et al., 2005). In this study, however, we clarified and characterized the inhibitory effects of EGCG on COX-1 and TXAS activities by using microsomal enzymes both having cy-
tochrome c reductase activity and expressing COX-1 (70 kDa) and TXAS (58 kDa) proteins. This provides a novel information of EGCG-mediated antiplatelet activity.

MATERIALS AND METHODS

Materials
Collagen was obtained from the Chrono-Log Corporation (Havertown, PA, USA). (–)-Epigallocatechin-3-gallate (EGCG), aspirin, and other reagents were obtained Sigma Chemical Corporation (St. Louis, MO, USA). COX-fluorescent activity assay kit and thromboxane A₂ synthase substrate prostaglandin H₂ were purchased from Cayman Chemical Co. (Ann Arbor, MI, USA). Cytochrome c reductase (NADPH) assay kit and other reagents were obtained Sigma Chemical Corporation (St. Louis, MO, USA). All other chemicals and reagents used in the present study were of the analytical grade.

Preparation of rat washed platelets
We prepared rat washed platelets to obtain microsomal fraction, a source of COX-1 and TXAS. Blood was collected from Sprague-Dawley (SPD) rats (6-7 weeks, male), and antioxidant with acid-citrate-dextrose (ACD) solution (0.8% citric acid, 2.2% sodium citrate, 2.45% glucose). Platelet-rich plasma was centrifuged at 125 × g for 10 min to remove the red blood cells, and the platelets were washed twice with washing buffer (138 mM NaCl, 2.7 mM KCl, 12 mM NaHCO₃, 0.36 mM NaHPO₄, 5.5 mM glucose, and 1 mM EDTA, pH 7.4). The washed platelets were then resuspended in suspension buffer (138 mM NaCl, 2.7 mM KCl, 12 mM NaHCO₃, 0.36 mM NaHPO₄, 0.49 mM MgCl₂, 5.5 mM glucose, 0.25% gelatin, pH 7.4) to a final concentration of 5×10⁷ platelets/ml containing suspension buffer (pH 7.4) with 1% protease inhibitor were sonicated at sensitivity 100% for 20 sec, 1 cycle, and 10 times on ice with a sonicator (Bandelin, HD2070, Germany) to obtain platelets sensitivity 100% for 20 sec, 1 cycle, and 10 times on ice with a sonicator (Bandelin, HD2070, Germany) to avoid platelet aggregation. The experimental results are expressed as the means ± S.E.M. accompanied by the numbers of observations. Data were assessed by analysis of variance (ANOVA). If this analysis indicated significant differences among the group means, then each group was compared by the Newman-Keuls method. p less than 0.05 was considered statistically significant.

RESULTS

Determination of enzyme source of COX-1 and TXAS
In our previous reports (Ok et al., 2012), we reported that the amount of TXA₂ (determined as TXB₂) in intact platelets was 4.0 ± 0.1 ng/10⁶ platelets, and this was markedly increased to 356.1 ± 46.9 ng/10⁶ platelets when platelets were stimulated with collagen (10 µg/ml) (Ok et al., 2012). EGCG (50 µM), however, powerfully reduced TXA₂ production to 89.5% (Ok et al., 2012). These results show that EGCG may inhibit the activity of COX-1 or TXAS to suppress the production of TXA₂ in collagen-induced platelet aggregation. Therefore, to deter-
mine whether the suppression of TXA₃ by EGCG was involved in inhibition of COX-1 or TXAS, we needed enzyme sources expressing both COX-1 and TXAS proteins. Therefore, we separated F1-, F2-, and F3-cellular fractions from platelet lysates, and measured the activity of cytochrome c reductase, an endoplasmic reticulum (microsomes) marker enzyme. As shown in Fig. 1A, we found that the F2-cellular fraction has the highest specific activity of cytochrome c reductase. Next, we determined which fraction from platelet lysates expresses both COX-1 and TXAS proteins. As the result, remarkably high expressions of COX-1 (70 kDa) and TXAS (58 kDa) were observed in F2-cellular fraction (Fig. 1B). Because these are accordance with that F2-cellular fraction has the highest activity of cytochrome c reductase, it is thought that F2-cellular fraction is microsomal fraction. This microsomal fraction was used to determine the activity of COX-1 and TXAS.

**Effects of EGCG on COX-1 and TXAS activities**

As shown in Fig. 2B, COX-1 activity in the absence of EGCG (control) was 1.59 ± 0.11 nmol/min/protein-mg. However, EGCG inhibited dose-dependently COX-1 activity, and EGCG at 50 μM inhibited COX-1 activity to 96.9% as compared with that (1.59 ± 0.11 nmol/min/protein-mg) of control (Table 1). TXAS activity in EGCG-untreated control was 0.14 ± 0.01 nmol/min/protein-mg. However, EGCG (50 μM) inhibited TXAS activity to 0.14 ± 0.01 nmol/min/protein-mg. In addition, 11 mM of ozagrel used as a positive control inhibited strongly TXAS activity to 0.14 ± 0.01 nmol/min/protein-mg. In addition, 0.01 nmol/min/protein-mg. However, EGCG (50 μM) inhibited TXAS activity to 0.02 ± 0.00 nmol/min/protein-mg (Fig. 3). The inhibitory degree by 50 μM of EGCG in TXAS activity was 20% (Table 1). Comparing the inhibitory effects of EGCG (50 μM) in COX-1 and TXAS activities, the inhibitory degree (96.9%) of COX-1 by EGCG is about 4.8 fold high as compared with that (20%) of TXAS (Table 1). We next investigated the effect of aspirin, COX-1 inhibitor, on inhibition of COX-1 activity.

**Effects of aspirin on COX-1 activity**

As shown in Fig. 4, various concentrations of aspirin (50 to 800 μM) inhibited mildly COX-1 activity (Fig. 4). Fifty μM of aspirin that corresponds to EGCG inhibiting COX-1 activity to 96.9% inhibited COX-1 activity to 11.3% (Table 2). The inhibitory degree ratio of EGCG (50 μM) to aspirin (50 μM) is calculated as 8.6, which means that EGCG (50 μM) has stronger inhibitory effect of 8.6 fold than aspirin (50 μM) on COX-1 activity. In addition, 100 μM of aspirin suppressed control activity (1.59 ± 0.11 nmol/min/mg-protein/min) to 1.36 ± 0.10 nmol/protein-mg/min (inhibition of 14.5%) (Fig. 4, Table 2). We analyzed the combination effect (Berenbaum, 1989; Gaddum, 1940) of EGCG (50 μM) with aspirin (100 μM) on COX-1 activity inhibition. Basal COX-1 activity (1.59 ± 0.11 nmol/mg-protein/min) was inhibited to 14.5 % by aspirin (100 μM) (Table 2). In the presence of both EGCG (50 μM) and aspirin (100 μM), COX-1 activity was inhibited 98.7% as compared with that of basal activity (Table 2), which inhibitory degree (98.7%) is lower than the sum (111.4%) of the inhibitory degree (96.9%) by EGCG (50 μM), and the inhibitory degree (14.5%) by aspirin (100 μM). This means that the combination of EGCG (50 μM) and aspirin (100 μM) has no combination effect on COX-1 activity, but may have antagonistic effect each other. The inhibitory...
degree of COX-1 by aspirin was largely beyond the scope of those concentrations (50 to 800 μM) (Fig. 4). IC₅₀ value of aspirin in COX-1 inhibition could not be calculated.

Effects of EGCG on COX-1 protein expression

Western blot analyses were carried out to investigate if the inhibition of COX-1 by EGCG or aspirin is resulted from suppression of COX-1 protein (70 kDa) expression. As shown in Fig. 5, the degree of COX-1 protein expression by various concentration (10 to 50 μM) of EGCG, and aspirin (50, 100 μM) were not altered as compared with that of control, without of EGCG or aspirin. These results suggest that the inhibition of COX-1 activity by EGCG or aspirin is independent on reduction in amount of COX-1 protein, COX-1 mRNA.

DISCUSSION

TXA₂ is generated from arachidonic acid (AA) released when membrane phospholipids are broken down by diverse agonists such as collagen, thrombin, and ADP (Hamberg et al., 1975; Samuelsson et al., 1978; Gresele et al., 1991). In previous our report (Ok et al., 2012), it was obvious that EGCG elevates cAMP without affecting cGMP to reduce intracellular Ca²⁺, required for the release of TXA₂ precursor AA from platelet membrane phospholipids. EGCG is also known to inhibit collagen-induced phospholipase Cγ₂ activity to reduce intracellular Ca²⁺ mobilization and TXA₂ production (Jin et al., 2008). TXA₂ is a strong agonist on resting platelets as a positive feedback promoter on activated platelets (Ruggeri, 2002; Jennings, 2009), and is also a vasoconstrictor and a bronchoconstrictor (FitzGerald, 1991). Thus, a compound that can inhibit TXA₂ production-associated enzymes (COX-1 or TXAS), TXA₂ production or TXA₂ action has a potential application as an anti-thrombotic agent (Clutton et al., 2001). Phytochemicals such as ginseng saponin (Lee et al., 2012), chlorogenic acid (Cho et al., 2012), caffedymine (Park, 2007) and sanguinarine (Jeng et al., 2007) inhibited TXA₂ production in agonists-stimulated platelets, which were involved in inhibition of COX-1 activity. These previous reports are accord with fact that the inhibition of agonists-induced platelet aggregation is supported by inhibition of COX-1 rather than TXAS (Lewis and Watts, 1982; Jang et al., 2002). This is supported from result that EGCG inhibits potently COX-1 activity to 96.9%, but mildly inhibited TXAS activity to 20% as compared with those of control (Fig. 2B, 3, Table 1). Because these results suggest that inhibition of TXA₂ by EGCG (Ok et al., 2012) is responsible for the suppression of microsomal COX-1 rather than TXAS, it is shown that EGCG may be used as a COX-1 inhibitor. In addition, it is known that EGCG elevated prostaglandin D₂ (PGD₂), an inhibitor of platelet aggregation, even though EGCG did not inhibit COX-1 and TXAS activities in AA-induced platelet aggregation (Jin et al., 2008). Because intracellular PGD₂ is known to elevate cAMP level to inhibit platelet aggregation (Armstrong, 1996), EGCG that only elevates Ca²⁺-antagonistic cAMP level (Ok et al., 2012) may involve also in inhibition of Ca²⁺-mobilization (Jin et al., 2008; Ok et al., 2012), then Ca²⁺-dependent phospholipase Cγ₂ (PLCγ₂) is inhibited by EGCG, which is resulted in inhibition of AA release from membrane phosphatidylinositol 1,4,5-tri-

| Table 1. Inhibitory degree of EGCG in COX-1- and TXAS-activities  |
|-----------------|-----------------|-----------------|-----------------|
|                  | COX-1           | TXAS            |                  |
|                  | (nmol/protein-mg/min) | (nmol/protein-mg/min) |                  |
| Control         | 1.59 ± 0.11     | 0.18 ± 0.01     | 0.05 ± 0.04     |
| EGCG (50 μM)    | 0.05 ± 0.04     | 96.9            | 0.14 ± 0.01     |

Data were from Fig. 2B, and Fig. 3. Inhibition (%) = (Control–EGCG (50 μM)) / Control× 100. COX-1 / TXAS: inhibitory ratio of COX-1 to TXAS by EGCG.

![Fig. 3. Effect of EGCG on thromboxane synthease activity](image-url)

![Fig. 4. Effects of aspirin on COX-1 activity.](image-url)
sphosphatase (Jin et al., 2008). Therefore, EGCG might have multiple action modes, such as cAMP elevation, PLC\(_\gamma\_2\) inhibition, Ca\(^{2+}\)-mobilization inhibition and VASP-Ser\(^{157}\) phosphorylation, to inhibit platelet aggregation (Jin et al., 2008; Ok et al., 2012). IC\(_{50}\) value of a substance is contributed to understand the inhibitory sensitivity against an enzyme activity. Jeng et al. (2007) reported the IC\(_{50}\) value of sanguinarine in COX-1 inhibition, phytochemical, is 28 \(\mu M\). In this study, IC\(_{50}\) value of EGCG in inhibition of COX-1 activity was calculated as 3.37 \(\mu M\) (Fig. 2), which value is lower than sanguinarine. It was obvious that the inhibition of COX-1 activity by EGCG is independent on reduction of COX-1 protein expression (Fig. 5), indicating reduction of COX-1 mRNA. It is known that aspirin is involved in inhibition of COX-1 activity via acetylation of COX-1 protein (Roth et al., 1975; Dewitt et al., 1990). At present, it is unknown how EGCG inhibits COX-1 activity, and if EGCG acetylates COX-1 protein in the same as aspirin. With regard to this, further more study is necessary in the future. It is known that increased cellular cAMP selectively inhibits COX-1 activity without altering COX-1 protein expression in bovine aortic endothelial cells (Samokovlsky et al., 1999). In special, platelet COX-1 activity is known to inhibit by cAMP (Schafer et al., 1980). Considering these reports (Schafer et al., 1980; Samokovlsky et al., 1999), and the effects of EGCG that increases markedly cAMP via adenylyl cyclase activation and subsequently phosphorylates VASP-Ser\(^{157}\) through A-kinase activation to inhibit Ca\(^{2+}\)-mobilization and TXA\(_2\) production on collagen-induced platelet aggregation (Ok et al., 2012), it is thought that EGCG might involve in inhibition of COX-1 activity (Fig. 2B) by stimulating adenylyl cyclase/cAMP/A-kinase/VASP-Ser\(^{157}\) phosphorylation pathway. Aspirin for the prevention of cardiovascular disease is known to increase the risk of gastrointestinal bleeding, cerebral haemorrhage (Samnuganathan et al., 2001; Pignone and Williams, 2010). EGCG from traditional green tea, one of the most popular beverages, may be used to treat platelet-mediated thrombotic disease by inhibiting potently TXA\(_2\) production (Ok et al., 2012). It is known that EGCG inhibits prostate- and colon- carcinogenesis by suppressing COX-2 protein expression (Hussain et al., 2005; Peng et al., 2006). PGE\(_2\) that is produced from AA by COX-2/PGE\(_2\) synthase results in inflammation (Trebino et al., 2003). If so, it is thought that EGCG may have also anti-inflammatory effect by inhibiting COX-2 activity in inflammatory leukocytes, in the same way as EGCG has anti-prostate and colon carcinogenic effects by inhibiting COX-2 activity (Hussain et al., 2005; Peng et al., 2006). Because both COX-1/TXA\(_2\)-pathway-induced platelet aggregation and COX-2/PGE\(_2\)-pathway-induced inflammation are the cause of atherosclerosis, it is thought that EGCG could contribute to the treatment of cardiovascular disease.

**ACKNOWLEDGMENTS**

This study was supported by a grant (2012-0002802 to Hwa-Jin Park) from the Basic Science Research Program via the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology, Korea.

**REFERENCES**

Armstrong, R. A. (1996) Platelet prostaglandin receptors. Pharmacol. Ther. 72, 171-191.

Berenbaum, M. C. (1989) What is synergy? Pharmacol. Rev. 41, 93-141.

Carey, F., Menashi, S. and Crawford, N. (1982) Localization of cyclooxygenase and thromboxane synthase in human platelet intracellular membranes. Biochem. J. 204, 847-851.

Cho, H. J., Kang, H. J., Kim, Y. J., Lee, D. H., Kwon, H. W., Kim, Y. Y. and Park, H. J. (2012) Inhibition of platelet aggregation by chlorogenic acid via cAMP and cGMP-dependent manner. Blood Coagul. Fibrinolysis 23, 629-635.

Clutton, P., Folts, J. D. and Freedman, J. E. (2001) Pharmacological control of platelet function. Pharmacol. Res. 44, 255-264.

Deana, R., Turetta, L., Donella-Deana, A., Dona, M., Brunati, A. M., Dimichiel, L. and Garbisa, S. (2003) Green tea epigallocatechin-3-gallate inhibits platelet signaling pathways triggered by both proteolytic and non-proteolytic agonists. Thromb. Haemost. 89, 866-874.

DeWitt, D. L., el-Harith, E. A., Kraemer, S. A., Andrews, M. J., Yao, E. F., Armstrong, R. L. and Smith, W. L. (1990) The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases. J. Biol. Chem. 265, 5192-5198.

FitzGerald, G. A. (1991) Mechanisms of platelet activation: thromboxane A\(_2\) as an amplifying signal for other agonists. Am. J. Cardiol. 68, 11B-15B.

Gaddum, J. H. (1940) Pharmacology. Oxford University Press, London, 378-383.

Gresele, P., Deckyym, H., Nenci, G. G. and Vernylen, J. (1991) Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders. Trends Pharmacol. Sci. 12, 158-163.

Hambeg, M., Svensson, J. and Samuelsson, B. (1975) Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl. Acad. Sci. USA 72, 2994-2998.
Hussain, T., Gupta, S., Adhami, V. M. and Mukhtar, H. (2005) Green tea constituent epigallocatechin-3-gallate selectively inhibits COX-2 without affecting COX-1 expression in human prostate carcinoma cells. *Int. J. Cancer* **113**, 660-669.

Jang, E. K., Azzam, J. E., Dickinson, N. T., Davidson, M. M. and Haslam, R. J. (2002) Roles for both cyclic GMP and cyclic AMP in the inhibition of collagen-induced platelet aggregation by nitroprusside. *Br. J. Haematol.* **117**, 664–675.

Jeng, J. H., Wu, H. L., Lin, B. R., Lan, W. H., Chang, H. H., Ho, Y. S., Lee, P. H., Wang, Y. J., Wang, J. S., Chen, Y. J. and Chang, M. C. (2007) Antiplatelet effect of sanguinarine is correlated to calcium mobilization, thromboxane and cAMP production. *Atherosclerosis* **191**, 250-258.

Jennings, L. K. (2009) Role of platelets in atherothrombosis. *Am. J. Cardiol.* **103**, 4A-10A.

Jin, Y. R., Im, J. H., Park, E. S., Cho, M. R., Han, X. H., Lee, J. J., Lim, Y., Kim, T. J. and Yun, Y. P. (2008) Anti-platelet activity of epigallocatechin gallate is mediated by the inhibition of PLCr2 phosphorylation, elevation of PGD2 production, and maintaining calcium-ATPase activity. *J. Cardiovasc. Pharmacol.* **51**, 45-54.

Lagarde, M., Menashi, S. and Crawford, N. (1981) Localisation of phospholipase A2 and diglyceride lipase activities in human platelet intracellular membranes. *FEBS Lett.* **124**, 23-26.

Lee, D. H., Cho, H. J., Kang, H. Y., Rhee, M. H. and Park, H. J. (2012) Total saponin from Korean red ginseng inhibits thromboxane A2 production associated microsomal enzyme activity in platelets. *J. Ginseng. Res.* **36**, 40-46.

Lewis, G. P. and Watts, I. S. (1982) Prostaglandin endoperoxides, thromboxane A2, and adenosine diphosphate in collagen-induced aggregation of rabbit platelets. *Br. J. Pharmacol.* **75**, 623-631.

Li, Z., Delaney, M. K., O’Brien, K. A. and Du, X. (2010) Signaling during platelet adhesion and activation. *Arterioscler. Thromb. Vasc. Biol.* **30**, 2341-2349.

Lill, G., Voit, S., Schor, K. and Weber, A. A. (2003) Complex effects of different green tea catechins on human platelets. *FEBS Lett.* **546**, 265-270.

Malmsten, C., Hamberg, M., Svensson, J. and Samuelsson, B. (1975) Physiological role of an endoperoxide in human platelets: hemo- static defect due to platelet cyclooxygenase deficiency. *Proc. Natl. Acad. Sci. USA* **72**, 1446-1450.

Mancuso, M., Filosto, M., Bosetti, F., Ceravolo R., Rocchi, A., Tognoni, G, Manca, M. L., Soliani, G., Siciliano, G. and Murri, L. (2003) Decreased platelet cytochrome c oxidase activity is accompanied by increased blood lactate concentration during exercise in patients with Alzheimer disease. *Exp. Neurol.* **182**, 421-426.

Ok, W. J., Cho, H. J., Kim, H. H., Lee, D. H., Kang, H. Y., Kwon, H. W., Rhee, M. H., Kim, and Park H. J. (2012) Epigallocatechin-3-gallate has an anti-platelet effect in a cyclic AMP-dependent manner. *J. Atheroscler. Thromb.* **19**, 337-348.

Park, J. B. (2007) Caffeoylquinic acid from cocoa has COX inhibitory activity suppressing the expression of a platelet activation marker, p-selectin. *J. Agric. Food Chem.* **55**, 2171-2175.

Patrano, C. (2001) Aspirin: New cardiovascular uses for an old drug. *Am. J. Med.* **110**, 62S-65S.

Peng, G., Dixon, D. A., Muga, S. J., Smith, T. J. and Wargovich, M. J. (2006) Green tea polyphenol (-)-epigallocatechin-3-gallate inhibits cyclooxygenase-2 expression in colon carcinogenesis. *Mol. Carcinog.* **45**, 309-319.

Pignone, M. and Williams, C. D. (2010) Aspirin for primary prevention of cardiovascular disease in diabetes mellitus. *Nat. Rev. Endocrinol.* **6**, 619-628.

Roth, G. J., Stanford, N. and Majerus, P. W. (1975) Acetylation of prostaglandin synthase by aspirin. *Proc. Nat. Acad. Sci. USA* **72**, 3073-3076.

Ruggeri, Z. M. (2002) Platelets in atherothrombosis. *Nat. Med.* **8**, 1227-1234.

Samokovlisky, A., Rimon, G. and Danon, A. (1999) Differential regulation of cyclooxygenase isoenzymes by cAMP-elevating agents. *Eur. J. Pharmacol.* **378**, 203-211.

Samuelsson, B., Goldyne, M., Granstrom, E., Mamberg, M., Hammarstrom, S. and Malmsten, C. (1978) Prostaglandins and thromboxanes. *Annu. Rev. Biochem.* **47**, 997-1029.

Samgunathan, P. S., Ghahramani, P., Jackson, P. R., Wallis, E. J. and Ramsay, L. E. (2001) Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomized trials. *Heart* **85**, 265-271.

Schafer, A. I., Levine, S. and Handin, R. I. (1980) Regulation of platelet arachidonic acid oxygenation by cyclic AMP. *Blood* **56**, 853-858.

Schwartz, S. M., Heinmark, R. L. and Majesky, M. W. (1990) Developmental mechanisms underlying pathology of arteries. *Physiol. Rev.* **70**, 1177-1209.

Trebin, C. E., Stock, J. L., Gibbons, C. P., Naiman, B. M., Wachtman, T. S., Umland, J. P., Pandher, K., Lapointe, J. M., Saha, S., Roach, M. L., Carter, D., Thomas, N. A., Durschi, B. A., McNeish, J. D., Hambor, J. E., Jakobsen, P. J., Carty, T. J., Perez, J. R. and Audoly, L. P. (2003) Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase. *Proc. Nat. Acad. Sci. USA* **100**, 9044-9049.